San Diego-based biotechnology company Pfenex Inc. has made significant strides in the development of biosimilar therapeutics. With a focus on ophthalmology, the firm's lead product candidate PF582 is a biosimilar to Lucentis that is currently in Phase Ib/IIa clinical trials for patients with wet age-related macular degeneration. The company is poised for success as it continues to develop treatments for a wide range of health concerns.
Pfenex Inc's ticker is PFNX
The company's shares trade on the NYSE stock exchange
They are based in San Diego, California
There are 51-200 employees working at Pfenex Inc
It is http://www.pfenex.com/
Pfenex Inc is in the Healthcare sector
Pfenex Inc is in the Biotechnology industry
The following five companies are Pfenex Inc's industry peers: